Recombinant epoetins do not stimulate tumor growth in erythropoietin receptor-positive breast carcinoma models

Molecular Cancer Therapeutics

Volumn 5, Issue 2, 2006, Pages 347-355

  LaMontagne, Kenneth R ^a   Butler, Jeannene ^a   Marshall, Deborah J ^b   Tullai, Jennifer ^a   Gechtman, Ze'ev ^a   Hall, Chassidy ^c   Meshaw, Alan ^c   Farrell, Francis X ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^b CENTOCOR INC   (United States)

^c Piedmont Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ERYTHROPOIETIN RECEPTOR; HEMOGLOBIN; MITOGEN ACTIVATED PROTEIN KINASE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PACLITAXEL; PROTEIN KINASE B; RECOMBINANT ERYTHROPOIETIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CARCINOMA; CELL MIGRATION; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOSOL; ENZYME ACTIVATION; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN LOCALIZATION; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA; CELL HYPOXIA; CELL MOVEMENT; CELL PROLIFERATION; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HUMANS; MICE; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; PACLITAXEL; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, ERYTHROPOIETIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33644970398     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-05-0203     Document Type: Article

References (49)

1. Tilbrook PA, Klinken SP. Erythropoietin and erythropoietin receptor. Growth Factors 1999;17:25-35.
2. Ebert BL, Bunn HF. Regulation of the erythropoietin gene. Blood 1999; 94:1864-77.
3. Lacombe C, Mayeux P. Biology of erythropoietin. Haematologica 1998; 83:724-32.
4. Barbone FP, Johnson DL, Farrell FX, et al. New epoetin molecules and novel therapeutic approaches. Nephrol Dial Transplant 1999;14:80-4.
5. Jelkmann W, editor. Erythropoietin: molecular biology and clinical use. Johnson City (Tennessee): F.P. Graham Publishing Co.; 2003.
6. Henry DH, Bowers P, Romano MT, Provenzano R. Epoetin alfa. Clinical evolution of a pleiotropic cytokine. Arch Intern Med 2004;164:262-76.
7. Gabrilove JL, Cleeland CS, Livingston RB, et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001;19:2875-82.
8. Witzig TE, Silberstein PT, Loprinzi CL, et al. Phase III, randomized, double-blind study of epoetin alpha compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol 2005;23:2606-17.
9. Österborg A, Brandberg Y, Molostova V, et al. Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies. J Clin Oncol 2002;20:2486-94.
10. Cazzola M, Beguin Y, Kloczko J, et al. Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production. Br J Haematol 2003;122:386-93.
11. Vansteenkiste J, Pirker R, Massuti B, et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002;94:1211-20.
12. Hedenus M, Adriansson M, San Miguel J, et al. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br J Haematol 2003;122:394-403.
13. Rizzo JD, Lichtin AE, Woolf SH, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 2002;20:4083-107.
14. Rodgers GM, Cella D, Chanan-Khan A, et al. Cancer and treatment-related anemia. National Comprehensive Cancer Network clinical practice guidelines in Oncology-v.1.2005.
15. Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anemia undergoing radiotherapy: randomized, double-blind, placebo-controlled trial. Lancet 2003;362:1255-60.
16. Leyland-Jones B, Semiglazov V, Pawlicki M, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 2005;23:5960-72.
17. Mulcahy L. The erythropoietin receptor. Semin Oncol 2001;28: 19-23.
18. Juul SE, Yachnis AT, Christensen RD. Tissue distribution of erythropoietin and erythropoietin receptor in the developing human foetus. Early Hum Dev 1998;52:235-49.
19. Lappin T. The cellular biology of erythropoietin receptors. Oncologist 2003;8:15-8.
20. Anagnostou A, Liu Z, Steiner M, et al. Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci U S A 1994; 91:3974-8.
21. Yasuda Y, Fujita Y, Musha T, et al. Expression of erythropoietin in human female reproductive organs. Ital J Anat Embryol 2001;106: 215-22.
22. Westphal G, Niederberger E, Blum C, et al. Erythropoietin and G-CSF receptors in human tumor cells: expression and aspects regarding functionality. Tumori 2002;88:150-9.
23. Selzer E, Wacheck V, Kodym R, et al. Erythropoietin receptor expression in human melanoma cells. Melanoma Res 2000;10:421-6.
24. Arcasoy M, Amin K, Chou S-C, et al. Erythropoietin and erythropoietin receptor expression in head and neck cancer: relationship to tumor hypoxia. Clin Cancer Res 2005;11:20-7.
25. Dagnon K, Pacary E, Commo F, et al. Expression of erythropoietin and erythropoietin receptor in non-small cell lung carcinomas. Clin Cancer Res 2001;11:993-9.
26. Lee Y-S, Vortmeyer AO, Lubensky IA, et al. Coexpression of erythropoietin and erythropoietin receptor in von Hippel-Lindau disease-associated renal cysts and renal cell carcinoma. Clin Cancer Res 2005;11:1059-64.
27. Acs G, Acs P, Beckwith SM, et al. Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res 2001;61:3561-5.
28. Acs G, Zhang PJ, Rebbeck TR, et al. Immunohistochemical expression of erythropoietin and erythropoietin receptor in breast carcinoma. Cancer 2002;95:969-81.
29. Arcasoy MO, Amin K, Karayal AF, et al. Functional significance of erythropoietin receptor expression in breast cancer. Lab Invest 2002; 82:911-8.
30. Farrell F, Lee A. The erythropoietin receptor and its expression in tumor cells and other tissues. Oncologist 2004;9:18-30.
31. Rosti V, Pedrazzoli P, Ponchio L, et al. Effect of recombinant human erythropoietin on hematopoietic and non-hematopoietic malignant cell growth in vitro. Haematologica 1993;78:208-12.
32. Ludwig H. rHuEPO and treatment outcomes: the preclinical experience. Oncologist 2004;9:48-54.
33. Westenfelder C, Baranowski RL. Erythropoietin stimulates proliferation of human renal carcinoma cells. Kidney Int 2000;58:647-57.
34. Kumar S, Acs G, Fang D, et al. Functional erythropoietin autocrine loop in melanoma. Am J Pathol 2005;166:823-30.
35. Anagnostou A, Lee ES, Kessimian N, et al. Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci U S A 1990;87:5978-82.
36. Emanuel S, Rugg CA, Gruninger RH, et al. The in vitro and in vivo effects of JNJ-7706621: a dual inhibitor of cyclin-dependent kinases and Aurora kinases. Cancer Res 2005;65:9038-46.
37. Richmond TD, Chohan M, Barber DL. Turning cells red: signal transduction mediated by erythropoietin. Trends Cell Biol 2005;15: 1146-55.
38. Batra S, Perelman N, Luck RL, Shimada H, Malik P. Pediatric tumor cells express erythropoietin receptor that promotes angiogenesis and tumor cell survival. Lab Invest 2003;83:1477-87.
39. Acs G, Xu X, Chu C, Acs P, Verma A. Prognostic significance of erythropoietin expression in human endometrial carcinoma. Cancer 2004;100:2376-86.
40. Acs G, Zhang PJ, McGrath CM, et al. Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression. Am J Pathol 2003;162:1789-806.
41. Stage-Marroquin B, Pech N, Goldwasser E. Internal autocrine regulation by erythropoietin of erythroleukemic cell proliferation. Exp Hematol 1996;24:1322-6.
42. Clark R. Human breast-cancer xenografts as models of the human disease. In: Teicher BA, editor. Tumor models in cancer research. Totowa (New Jersey): Humana Press; 2002. p. 453-70.
43. Spivak JL. The anaemia of cancer: death by a thousand cuts. Nat Rev Cancer 2005;5:543-55.
44. Elliott SG, Lorenzini T, Strickland T, Delorme E, Egrie JC. Rational design of novel erythropoiesis stimulating protein (Aranesp): a super-sialated molecule with increased biological activity. Blood 2000;96:82-3a. Abstract 352 and poster.
45. Masuda S, Nagao M, Takahata K, et al. Functional erythropoietin receptor of the cells with neural characteristics. Comparison with receptor properties of erythroid cells. J Biol Chem 1993;268:11208-16.
46. Busse L, Sinclair A, Rogers N, Sarosi I, Van G, Elliott S. Is EPO receptor over-expressed in human tumor cells [abstract 4562]? Proc Am Assoc Cancer Res 2005;46:1077.
47. Komatsu N, Kirito K, Kashii Y, et al. Cell-cycle-dependent regulation of erythropoietin receptor gene. Blood 1997;89:1182-8.
48. Blackwell KL, Kirkpatrick JP, Snyder SA, et al. Human recombinant erythropoietin significantly improves tumor oxygenation independent of its effects on hemoglobin. Cancer Res 2003;63:6162-5.
49. Sigounas G, Sallah S, Sigounas VY. Erythropoietin modulates the anticancer activity of chemotherapeutic drugs in a murine lung cancer model. Cancer Lett 2004;214:171-9.